Satellos Bioscicence Inc.

Summary:

• Satellos Bioscience Inc. is a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders.

• SAT-3247, the Company’s lead drug candidate, is poised to enter clinical development in a Phase 1 clinical trial in Q3, 2024. A novel small molecule drug designed to be taken by mouth, SAT-3247 has been specifically designed by Satellos to target the root cause of muscle loss in degenerative diseases initially in Duchenne muscular dystrophy (“Duchenne” of “DMD”). Satellos discovered a means to restore the body’s innate skeletal muscle repair and regeneration process.

• SAT-3247 presents a first-in-class therapeutic drug with an entirely novel approach that has the potential for broad applications beyond Duchenne including other dystrophies, diseases of aging, and trauma and injury.